Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100686 | 0.79 | CHRM1 (0.54) | CHRM1GRM5GRM1 | |
| SCHEMBL20100691 | 0.78 | CHRM1 (0.43) | CHRM1 | |
| SCHEMBL20100689 | 0.78 | CHRM1 (0.56) | CHRM1 | |
| SCHEMBL20100685 | 0.75 | CHRM1 (0.38) | CHRM1 | |
| SCHEMBL20100687 | 0.74 | CHRM1 (0.34) | CHRM1 | |
| SCHEMBL20100690 | 0.74 | CHRM1 (0.33) | CHRM1 | |
| SCHEMBL20100695 | 0.70 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL20100693 | 0.70 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL20100696 | 0.70 | CHRM1 (0.55) | CHRM1 | |
| SCHEMBL19848948 | 0.70 | HTR1A (0.38) | CHRM1GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM5, CHRM4 | CHRM1 1/4885PSEN1 776/4885PSEN2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.